Analysts Anticipate Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Will Announce Earnings of -$0.17 Per Share

Wall Street brokerages forecast that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will post earnings per share of ($0.17) for the current quarter, Zacks reports. Three analysts have issued estimates for Aurinia Pharmaceuticals’ earnings, with estimates ranging from ($0.19) to ($0.14). Aurinia Pharmaceuticals posted earnings of ($0.21) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 19%. The firm is expected to report its next quarterly earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.58). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.66) per share, with EPS estimates ranging from ($1.09) to ($0.31). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 13,231.97% and a negative return on equity of 50.08%.



A number of brokerages recently commented on AUPH. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Aurinia Pharmaceuticals in a research report on Tuesday, June 4th. BidaskClub upgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $11.00 target price on shares of Aurinia Pharmaceuticals in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $15.65.

NASDAQ:AUPH traded up $0.26 during trading hours on Tuesday, reaching $5.90. The company’s stock had a trading volume of 691,400 shares, compared to its average volume of 498,713. The firm has a market capitalization of $517.92 million, a price-to-earnings ratio of -7.76 and a beta of 1.09. The firm has a 50-day simple moving average of $6.22 and a 200-day simple moving average of $6.37. Aurinia Pharmaceuticals has a 1 year low of $5.06 and a 1 year high of $7.85.

A number of large investors have recently modified their holdings of the stock. Lindbrook Capital LLC grew its holdings in Aurinia Pharmaceuticals by 200.0% in the 1st quarter. Lindbrook Capital LLC now owns 6,000 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 4,000 shares during the last quarter. Victory Capital Management Inc. bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth $45,000. Toronto Dominion Bank grew its holdings in Aurinia Pharmaceuticals by 64.7% in the 1st quarter. Toronto Dominion Bank now owns 9,780 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 3,842 shares during the last quarter. Spark Investment Management LLC bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth $71,000. Finally, UBS Asset Management Americas Inc. bought a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth $88,000. Institutional investors own 32.52% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Read More: Does a trade war provide a risk to the global economy?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.